| Multispecific NKp46 binding protein |
2022-12-15 |
2023-4-11 |
|
| Compositions and methods for treating cancer |
2022-11-25 |
2023-3-14 |
|
| Combination therapy using antibody to human siglec-9 and antibody to human … |
2022-9-19 |
2023-3-23 |
|
| Restoration of t cell activity via the cd39/cd73 axis |
2022-7-28 |
2023-3-30 |
|
| Compositions and methods for treating cancer |
2022-6-30 |
2023-1-26 |
|
| NKp46 BINDING AGENTS |
2022-6-29 |
2022-10-27 |
|
| VARIABLE REGION OF NKp46-BOUND PROTEIN |
2022-6-15 |
2022-9-21 |
|
| Multispecific proteins binding to nkp46, a cytokine receptor, a tumour antigen … |
2022-6-08 |
2022-12-15 |
|
| Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen … |
2022-6-08 |
2022-12-15 |
|
| Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen … |
2022-6-08 |
2022-12-15 |
|
| Multispecific antibodies binding to cd20, nkp46, cd16 and conjugated to il-2 |
2022-6-08 |
2022-12-15 |
|
| Cross reactive siglec antibodies |
2022-4-11 |
2022-7-28 |
|
| Immunohistochemistry methods and kir3dl2-specific reagents |
2022-4-04 |
2022-10-13 |
|
| Multispecific proteins comprising an nkp46-binding site, a cancer antgienge … |
2022-3-24 |
2022-9-29 |
|
| Multifunctional natural killer (nk) cell engagers binding to nkp46 and cd123 |
2021-12-30 |
2022-7-07 |
|
| Treatment of cancer |
2021-11-24 |
2022-6-02 |
|
| Multispecific antigen binding proteins |
2021-11-19 |
2022-5-05 |
|
| Cd73 blocking antibodies |
2021-10-22 |
2022-2-10 |
|
| Cd73 blockade |
2021-8-16 |
2021-9-16 |
|
| Subcutaneous anti-c5ar antagonist treatment regimen with avdoralimab |
2021-8-06 |
2022-2-17 |
|
| Subcutaneous anti-c5ar antagonist treatment regimen with avdoralimab |
2021-8-06 |
2022-2-17 |
|
| Cell surface mica and micb detection using antibodies |
2021-8-06 |
2022-2-17 |
|
| Cancer treatment methods using anti-cd73 antibodies |
2021-8-06 |
2022-4-14 |
|
| Compound that specifically binds to kir3dl2 for use in the treatment of … |
2021-7-29 |
2021-11-25 |
|
| Siglec neutralizing antibodies |
2021-7-29 |
2021-11-25 |
|
| Treatment of t cell lymphoma |
2021-7-21 |
2021-11-18 |
|
| Humanized antibodies with increased stability |
2021-7-15 |
2021-11-04 |
|
| Use of cd160 as a biomarker in acute myeloid leukemia |
2021-7-13 |
2022-1-20 |
|
| Leucocyte immunoglobulin-like receptor 2 neutralizing antibodies |
2021-6-16 |
2021-8-31 |
|
| Treatment regimens using anti-NKG2A antibodies |
2021-6-07 |
2021-7-01 |
|
| Neutralization of inhibitory pathways in lymphocytes |
2021-5-14 |
2021-7-23 |
|
| MULTISPECIFIC NKp46 BINDING PROTEINS |
2021-2-15 |
2021-3-11 |
|
| Treatment of cancer |
2021-1-28 |
2022-6-23 |
|
| Treatment with anti-kir3dl2 agents |
2020-12-08 |
2021-3-25 |
|
| Neutralization of inhibitory pathways in lymphocytes |
2020-10-14 |
2021-3-05 |
|
| Treatment of cancer with ilt-2 inhibitors |
2020-10-13 |
2021-4-22 |
|
| Treatment of head and neck cancer |
2020-9-07 |
2020-10-29 |
|
| Combination of monalizumab, durvalumab, chemotherapy and bevacizumab or … |
2020-5-06 |
2022-3-16 |
|
| Potentiating the effect of atp release |
2020-3-19 |
2020-5-31 |
|
| Mica binding agents |
2020-2-28 |
2020-9-24 |
|
| Kir3dl2 binding agents |
2020-2-28 |
2020-6-25 |
|
| ANTIBODY, PHARMACEUTICAL COMPOSITION, KIT AND METHOD TO PREDICT OR EVALUATE … |
2020-1-20 |
2021-9-28 |
|
| Treatment of colorectal cancer by a combination of an anti-mica antibody and an … |
2019-8-05 |
2020-2-20 |
|
| Treatment of peripheral t cell lymphoma |
2019-6-25 |
2019-10-17 |
|
| Treatment of cancers using anti-nkg2a agents |
2019-6-21 |
2019-10-24 |
|
| Cancer treatment |
2019-5-14 |
2021-1-27 |
|
| Methods for treating cancer by targeting nidogen-1 |
2019-4-24 |
2019-10-31 |
|
| Monoclonal antibodies against nkg2a |
2018-12-20 |
2019-5-09 |
|
| Multispecific antigen binding proteins |
2018-11-19 |
2020-10-15 |
|
| Antibodies with functionalized glutamine residues |
2018-11-08 |
2019-5-16 |
|
| Multispecific nk engager protein |
2018-10-29 |
2019-2-21 |
|
| Recognition tags for tgase-mediated conjugation |
2018-7-13 |
2019-6-06 |
|
| antibodies, agents, pharmaceutical composition, kit, nucleic acid, host cell, … |
2018-7-09 |
2020-7-14 |
|
| Siglec-9-neutralizing antibodies |
2018-7-09 |
2023-4-11 |
2023-4-11 |
| Compositions and methods for regulating nk cell activity |
2018-4-16 |
2018-10-04 |
|
| Immunomodulatory antibody drug conjugates binding to a human mica polypeptide |
2018-2-05 |
2018-8-09 |
|
| Heterodimeric antigen binding proteins |
2017-12-21 |
2019-10-24 |
|
| Nkp46 ligand |
2017-10-31 |
2018-5-11 |
|
| Anti-cd39 antibodies |
2017-10-05 |
2018-4-12 |
|
| Combination of anti-KIR and anti-CTLA-4 antibodies to treat cancer |
2017-9-13 |
2020-6-23 |
2020-6-23 |
| Enzymatic conjugation of antibodies |
2017-9-12 |
2018-7-12 |
|
| Isolated antibody or fragment thereof, nucleic acid encoding said antibody or … |
2017-7-07 |
2020-2-03 |
|
| METHODS AND COMPOSITIONS FOR INCREASING THE EFFECTIVENESS OF THERAPEUTIC … |
2017-4-07 |
2018-1-10 |
|
| Anti-mica antibodies |
2017-3-14 |
2017-9-21 |
|
| Anti-cd39 antibodies |
2017-3-14 |
2019-1-23 |
|
| Compositions and methods for treating proliferative disorders |
2017-2-17 |
2017-3-09 |
|
| Variable regions of NKp46 binding proteins |
2016-12-20 |
2023-4-07 |
|
| Cd39 vascular isoform targeting agents |
2016-11-22 |
2018-10-03 |
|
| Siglec-10 antibodies |
2016-11-17 |
2017-5-26 |
|
| Cd73 blocking agents |
2016-10-11 |
2018-8-22 |
|
| Enzymatic conjugation of polypeptides |
2016-7-19 |
2019-10-08 |
2019-10-08 |
| Tlr3 binding agents |
2016-7-07 |
2016-12-01 |
|
| Method for detecting tissue infiltration's NK cells |
2016-7-04 |
2018-3-27 |
|
| Multispecific antigen binding proteins |
2016-6-23 |
2020-2-13 |
|
| Nk cell modulating treatments and methods for treatment of hematological … |
2016-5-12 |
2016-12-01 |
|
| Cd73 blockade |
2016-2-19 |
2016-8-25 |
|
| Cd73 blockade |
2016-2-19 |
2018-2-01 |
|
| Monomeric fc domains |
2016-1-04 |
2023-3-07 |
2023-3-07 |
| Anti-kir3d antibodies |
2015-10-28 |
2016-2-18 |
|
| Neutralization of inhibitory pathways in lymphocytes |
2015-9-15 |
2021-11-30 |
|
| Treatment of celiac disease |
2015-8-27 |
2016-3-03 |
|
| Human anti-kir antibodies |
2015-8-18 |
2015-12-03 |
|
| Anti-kir antibodies for the treatment of inflammatory and autoimmune disorders |
2015-6-29 |
2015-12-31 |
|
| Monomeric multispecific antigen binding proteins |
2015-6-23 |
2015-12-30 |
|
| Kir-binding agents and methods of use thereof |
2015-3-23 |
2016-2-18 |
|
| Combination of anti-kir and anti-cs1 antibodies to treat multiple myeloma |
2014-11-05 |
2016-9-08 |
|
| Antibodies conjugated to at least one nucleic acid molecule and their use in … |
2014-6-27 |
2014-12-31 |
|
| Enzymatic conjugation of polypeptides |
2014-6-20 |
2014-12-24 |
|
| 多重特異的ＮＫｐ４６結合タンパク質 |
2022-12-15 |
2023-4-11 |
|
| Schema de traitement anti-antagoniste c5ar en sous-cutane avec avdoralimab |
2021-8-06 |
2022-2-17 |
|
| Anticorpo, composição farmacêutica, kit e método para predizer ou avaliar a … |
2020-1-20 |
2021-9-28 |
|
| NKp46结合蛋白的可变区 |
2016-12-20 |
2023-4-07 |
|